Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Acute Lymphoblastic Leukemia

Aliases
B Acute Lymphoblastic Leukemia

343 clinical trials

370 products

45 drugs

Clinical trial
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults With Acute Leukemia
Status: Recruiting, Estimated PCD: 2025-07-31
Product
BMF-500
Clinical trial
Expanded Access to Venetoclax
Status:
Product
Venetoclax
Product
EPZ-5676
Clinical trial
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Completed, Estimated PCD: 2015-11-01
Product
SNDX-5613
Product
cobicistat
Clinical trial
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Dose-escalation Sequention Cohort Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNR-084 in Patients With Refractory or Relapse Acute Lymphoblastic B-cell Precursor Leukemia.
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Cohort 3, GNR-084
Product
GNR-084
Product
ziftomenib
Clinical trial
Expanded Access to Ziftomenib
Status:
Clinical trial
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
Status: Recruiting, Estimated PCD: 2024-12-07
Product
Ponatinib
Clinical trial
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
BMF-219
Clinical trial
An Open-label, Multi-center Phase Ib/II Study of CN201 in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)
Status: Completed, Estimated PCD: 2023-12-18
Product
CN201
Product
Zilovertamab
Clinical trial
A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF INOTUZUMAB OZOGAMICIN IN CHINESE ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Status: Active (not recruiting), Estimated PCD: 2024-08-07
Product
Cohort 1, GNR-084
Product
Inotuzumab ozogamicin
Product
TGRX-814
Clinical trial
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2025-05-27
Clinical trial
A Single-arm, Open-label, Dose Escalation and Expansion Phase I/II Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-814 Monotherapy and Combination Therapy in Patients With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase 1b Open-label Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Administration of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2023-01-24
Product
AMG 404
Product
Blinatumomab
Product
Dexamethasone
Product
Orca-T
Clinical trial
A Phase Ib Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Inotuzumab Ozogamicin
Clinical trial
A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Standard-of-Care
Product
MGTA-145
Product
Plerixafor
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination With Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Terminated, Estimated PCD: 2021-09-14
Product
PTX-200
Product
Cytarabine
Clinical trial
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Status: Completed, Estimated PCD: 2023-10-31
Clinical trial
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemias or Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-12-30
Product
Cyclophosphamide
Product
Fludarabine
Product
BEAM-201
Product
Idasanutlin
Product
Topotecan
Product
Intrathecal Chemotherapy
Clinical trial
A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Status: Recruiting, Estimated PCD: 2031-12-01
Product
OrcaGraft
Clinical trial
A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Carfilzomib
Clinical trial
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-07-14
Product
Mitoxantrone
Product
Vincristine
Product
Daunorubicin
Product
PEG-asparaginase
Product
Methotrexate
Product
Intrathecal Triple Therapy
Product
6-Mercaptopurine
Product
Inotuzumab
Product
Brexucabtagene Autoleucel
Clinical trial
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Status:
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CCTL019B2003I to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)
Status:
Product
CTL019
Clinical trial
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Status: Completed, Estimated PCD: 2021-06-03
Product
Nilotinib
Product
Dasatinib
Product
Asciminib
Product
Imatinib
Clinical trial
Post-Marketing Surveillance of Safety and Effectiveness of Iclusig® Tablets in Korean Patients With CML or Ph+ ALL Under the "Risk Management Plan"
Status: Active (not recruiting), Estimated PCD: 2022-11-29
Clinical trial
An Open, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Quad-specific Antibody Injection in Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Acute Lymphoblastic Leukemia, and Refractory or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-11-01
Product
GNC-038
Clinical trial
A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT)
Status: Completed, Estimated PCD: 2009-11-30
Clinical trial
An Open-Label, Multicenter Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coli-derived Asparaginases
Status: Completed, Estimated PCD: 2022-07-13
Product
VCL-CB01
Product
CD19-UCART
Clinical trial
A Safety and Efficacy Study of CD19-UCART (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor) in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
Status: , Estimated PCD: 2023-12-15
Product
IM JZP-458
Product
JZP-458
Clinical trial
Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2023-02-24
Clinical trial
Clinical Study of the Safety and Efficacy of Next-generation Universal CD19 Chimeric Antigen Receptor T Cells in the Treatment of Relapsed or Refractory B Cell Malignancies
Status: Not yet recruiting, Estimated PCD: 2024-05-30
Product
TC-110
Clinical trial
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
An Open-label, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2019-08-21
Product
Dexamthasone
Product
CNCT19
Clinical trial
A Phase 1, Open-label Study to Assess the Mass Balance, Pharmacokinetics, and Metabolism of Orally Administered [14C]-SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemia
Status: Recruiting, Estimated PCD: 2024-05-01
Product
MB-CART19.1
Clinical trial
A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 2a, Multi-centre, Randomised, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine as an Add-on Therapy in Adults With Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2024-02-01
Product
Pyronaridine Tetraphosphate
Clinical trial
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2024-09-06
Clinical trial
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse
Status: Terminated, Estimated PCD: 2022-09-12
Clinical trial
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Status: Terminated, Estimated PCD: 2021-11-05
Product
L-Asparaginase
Product
MRX-2843
Product
Efprezimod
Product
Placebo
Product
Tacrolimus
Clinical trial
A Phase I Study to Evaluate the Safety and Immunogenicity of 3D189 in Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
An Open Label Evaluation Phase 1 Trial of the Safety and Pharmacokinetics of MRX-2843 in Adolescents and Adults With Relapsed/Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Mixed Phenotype Acute Leukemia
Status: Recruiting, Estimated PCD: 2024-07-31
Product
3D189
Product
Liposomal daunorubicin
Product
Idarubicin
Product
NiCord
Clinical trial
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Status: Terminated, Estimated PCD: 2020-06-01
Product
Isatuximab
Product
Filgrastim
Product
Doxorubicin
Product
Pegaspargase
Product
Etoposide
Product
CAR-T Autologous T cell
Product
BPX-501
Product
Rimiducid
Clinical trial
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2021-04-29
Product
Hydroxyurea
Clinical trial
Phase I, Open Label, Multicenter, Dose Escalation and Expansion Study of IMJ995 in Acute Lymphoblastic Leukemia
Status: Withdrawn, Estimated PCD: 2026-08-13
Clinical trial
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Status: Terminated, Estimated PCD: 2022-12-01
Product
AVM0703
Clinical trial
AVM0703-EAP
Status:
Clinical trial
A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2035-03-31
Product
Hydrocortisone
Product
Proton pump inhibitor
Product
TBI-1501
Product
ONO-7475
Product
ONO-7475 + Venetoclax
Clinical trial
A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
Status: Active (not recruiting), Estimated PCD: 2022-07-22
Product
Busulfan
Product
Mesna
Clinical trial
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Status: Recruiting, Estimated PCD: 2026-06-30
Product
Sirolimus
Product
Mycophenolate Mofetil
Product
IMJ995
Product
Humanized CD19 CAR-T cells
Clinical trial
Humanized Chimeric Antigen Receptor T Cells Against CD19 With Cytokine Release Syndrome (CRS) Suppression Technology for Refractory/Relapsed CD19+ Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2022-09-22
Product
rivogenlecleucel
Clinical trial
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Status: Terminated, Estimated PCD: 2020-06-30
Product
chemotherapy
Product
venetoclax
Clinical trial
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Status: Completed, Estimated PCD: 2023-04-19
Product
1A46
Product
CAR-NK-CD19 Cells
Clinical trial
A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase Ⅰ Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor Gene Modified NK Cells Targeting CD19 in Patients With Recurrent or Refractory CD19 Positive Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2022-11-25
Clinical trial
A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE
Status: Completed, Estimated PCD: 2022-09-21
Product
Systemic Treatment
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Status: Completed, Estimated PCD: 2020-12-04
Product
Control
Product
ProTmune
Clinical trial
Sirolimus+Abatacept+Mycophenolate Mofetil Regimen for Prophylaxis of Acute Graft-versus-host Disease (aGvHD) in Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HSCT) Who Are Intolerant to Calcineurin Inhibitor
Status: Not yet recruiting, Estimated PCD: 2024-06-01
Product
Abatacept
Drug
mycophenolate mofetil
Product
ATG
Clinical trial
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2019-04-03
Product
CD22-CAR
Clinical trial
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2021-06-07
Drug
CPX-351
Clinical trial
Personalized NK Cell Therapy in CBT
Status: Recruiting, Estimated PCD: 2025-05-31
Product
Allogeneic Natural Killer Cell Line NK-92
Clinical trial
Canadian-Led Immunotherapies in Cancer: CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2024-10-01
Product
CLIC-1901
Product
Anti-Thymocyte Globulin
Product
Clofarabine
Drug
cyclophosphamide
Clinical trial
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Active (not recruiting), Estimated PCD: 2019-03-31
Drug
fludarabine
Drug
Melphalan
Drug
Varlilumab
Clinical trial
Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2023-02-17
Clinical trial
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Reduced Intensity Allogeneic Stem Cell Transplant
Status: Not yet recruiting, Estimated PCD: 2028-02-01
Product
Ofatumumab
Product
Prednisone
Drug
Vincristine
Clinical trial
Multi-center Clinical Trial for Optimal Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Status: Not yet recruiting, Estimated PCD: 2029-12-31
Product
Non-Dasatinib
Clinical trial
Phase II Study of Blinatumomab in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Dose-Finding Phase Ib Study of the Oral BCL-2 Inhibitor Venetoclax (ABT-199) in Combination With Standard Induction Therapy, Dasatinib, Prednisone, (and Rituximab in CD20+ Patients) in Adult Patients With Newly Diagnosed and Relapsed Philadelphia Chromosome Positive ALL (Ph+ ALL) and Ph+ MPAL
Status: Recruiting, Estimated PCD: 2025-06-02
Clinical trial
A Preliminary Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 (CD19/CD22 CAR-T) in Adults With Recurrent or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2026-10-01
Product
KQ-2002 CAR-T cells
Product
Leucovorin Calcium
Product
Mercaptopurine
Clinical trial
Clinical Trial for the Safety and Efficacy of Induction Chemotherapy With Azacitidine+Venetoclax (VA) and Bridging CD19CD22 CAR-T Therapy in Adult Patients With Newly Diagnosed High-Risk and Ph-negative (Ph-) B-ALL
Status: Recruiting, Estimated PCD: 2024-09-10
Product
Azacitidine
Product
CD19CD22 CAR-T
Product
Thioguanine
Clinical trial
A Phase II Study Using a BFM Regimen Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Status: Withdrawn, Estimated PCD: 2026-01-01
Product
Berlin-Frankfurt-Münster Chemotherapy
Product
Methotrexate and Cytarabine
Clinical trial
A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)
Status: , Estimated PCD: 2023-01-13
Product
Cyclosporine
Clinical trial
A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Status: Terminated, Estimated PCD: 2012-01-10
Drug
R-CHOP
Clinical trial
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-02-09
Product
KYMRIAH
Clinical trial
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia
Status: , Estimated PCD: 2023-09-01
Product
YESCARTA
Clinical trial
Phase 2a Study of Adding Ruxolitinib With Tacrolimus/Methotrexate Regimen for Graft-versus-Host Disease Prophylaxis in Myeloablative Conditioning Hematopoietic Cell Transplantation in Pediatric and Young Adult Patients
Status: Not yet recruiting, Estimated PCD: 2027-10-31
Product
Ruxolitinib
Clinical trial
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Status: Active (not recruiting), Estimated PCD: 2018-02-01
Drug
Selinexor
Clinical trial
Phase II Study of Evaluating the Efficacy of Total Marrow and Lymphoid Irradiation (TMLI) as the Conditioning Regimen for HLA-Haploidentical Hematopoietic Cell Transplantation in Patients With Myelodysplasia or Acute Leukemia
Status: Recruiting, Estimated PCD: 2025-08-04
Product
Granulocyte Colony-Stimulating Factor
Product
Tecartus
Product
Abecma
Product
Breyanzi
Clinical trial
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Status: Recruiting, Estimated PCD: 2029-06-30
Product
Asparaginase
Clinical trial
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Status: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)
Status: Active (not recruiting), Estimated PCD: 2017-09-30
Clinical trial
A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Status: Recruiting, Estimated PCD: 2026-08-01
Product
AKR1C3-activated Prodrug OBI-3424
Product
Prednisolone
Drug
Filgrastim
Product
Lestaurtinib
Product
Leucovorin
Clinical trial
A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma
Status: Withdrawn, Estimated PCD: 2026-09-22
Product
Calaspargase Pegol
Clinical trial
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Thiotepa
Product
Methylprednisolone
Clinical trial
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Status: Recruiting, Estimated PCD: 2030-03-31
Clinical trial
Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy as Consolidation and Maintenance Therapy for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Drug
dasatinib
Drug
Ketamine
Drug
methotrexate
Clinical trial
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Status: Completed, Estimated PCD: 2023-12-20
Product
T cells (Tcon) and Regulatory T cells (Treg)
Clinical trial
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Metabolically Armed CD19 CAR-T cells
Clinical trial
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Status: Completed, Estimated PCD: 2020-01-30
Clinical trial
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Status: Active (not recruiting), Estimated PCD: 2022-05-10
Product
ITMHA
Product
Asparaginase Erwinia Chrysanthemi
Product
Bortezomib
Product
Vorinostat
Product
Navitoclax
Product
Nelarabine
Clinical trial
A Study of CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
Status: Recruiting, Estimated PCD: 2027-05-30
Product
CD19-BAFF Targeted CAR T-cells
Clinical trial
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2026-10-05
Product
Mini-hyper CVD
Clinical trial
INITIALL: Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Status: Not yet recruiting, Estimated PCD: 2034-05-01
Clinical trial
A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2026-01-01
Product
PRGN-3007
Product
G-csf
Product
Intrathecal triple therapy
Product
TCRα/β+
Product
CD19+
Product
CD45RA-depleted DLI
Clinical trial
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
Status: Not yet recruiting, Estimated PCD: 2032-12-31
Product
Blincyto
Clinical trial
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Status: Recruiting, Estimated PCD: 2027-03-01
Product
Nivolumab
Clinical trial
Randomized Trial to Study the Effect of Rifaximin on Gut Microbiome Diversity Post Allogeneic Stem Cell Transplant in Acute Leukemia.
Status: Not yet recruiting, Estimated PCD: 2026-10-15
Product
Rifaximin
Clinical trial
A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells
Status: Active (not recruiting), Estimated PCD: 2023-08-28
Clinical trial
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Status: Recruiting, Estimated PCD: 2028-07-14
Product
Myocet
Clinical trial
Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Alpha Beta Depletion
Clinical trial
A Phase I/II Study to Investigate the Combination of LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory T-ALL/LBL
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
LP-118
Clinical trial
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2026-05-05
Product
Acetaminophen
Product
Ifosfamide
Product
Tioguanin
Product
Vindesine
Product
Erwinase
Clinical trial
Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab in Patients With Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplantation
Status: Withdrawn, Estimated PCD: 2021-05-31
Clinical trial
A Feasibility Study Following a Phase 2a Design to Demonstrate Successful Local Manufacture of Chimeric Antigen Receptor (CAR) T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2037-08-05
Product
Chimeric Antigen Receptor (CAR) T-Cell Product
Clinical trial
Phase IIa Study of Addition of Itacitinib With Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melphalan Non-Myeloablative Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, MDS or MF
Status: Active (not recruiting), Estimated PCD: 2023-05-22
Product
Itacitinib
Clinical trial
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group
Status: Completed, Estimated PCD: 2023-07-31
Product
SR-A + Epratuzumab
Product
SR-B + Epratuzumab
Clinical trial
Phase I Safety and Tolerability Trial of CD19 Directed CAR T Cells in Adult Patients With B-Cell Acute Lymphoblastic Leukemia (B-ALL) With Minimal Residual Disease (MRD) Positivity at First Complete Remission
Status: Recruiting, Estimated PCD: 2025-07-01
Product
CD19 Directed CAR T Cell
Clinical trial
Evaluation of Safety and Efficacy of CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Concomitant With Infusion of CD19+T Cells as Feeding Cells
Status: Recruiting, Estimated PCD: 2024-06-30
Product
CD19 CAR-T cells infusion combined with feeding T cells
Clinical trial
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Status: Active (not recruiting), Estimated PCD: 2025-02-28
Clinical trial
Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Pegfilgrastim
Clinical trial
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Recruiting, Estimated PCD: 2027-07-01
Product
CD19/CD22-CAR-transduced T cells
Clinical trial
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group
Status: Recruiting, Estimated PCD: 2027-12-31
Product
Flotetuzumab
Clinical trial
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination With Azacitidine in Subjects With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
LP-108
Clinical trial
Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022)
Status: Not yet recruiting, Estimated PCD: 2028-12-25
Clinical trial
Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2028-12-31
Product
SNUH-CD19-CAR-T
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
A Randomized, Multicenter, Open-label Phase II Trial to Compare Prophylaxis of Graft Versus Host Disease With Tacrolimus and Mycophenolate Mofetil Versus Ruxolitinib After Post-transplant Cyclophosphamide
Status: Active (not recruiting), Estimated PCD: 2023-02-27
Clinical trial
Interfant-21 International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL
Status: Recruiting, Estimated PCD: 2027-06-30
Product
Rapcabtagene autoleucel
Product
Ibrutinib
Clinical trial
Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Product
Autologous CD22 CAR T
Clinical trial
Phase I/II Study of Oral ONC201 in Patients With Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2024-11-30
Product
Akt/ERK Inhibitor ONC201
Clinical trial
Phase I/II Trial of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Status: Withdrawn, Estimated PCD: 2025-12-01
Drug
Sitagliptin
Clinical trial
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Status: , Estimated PCD: 2027-10-16
Product
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
Clinical trial
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Status: Terminated, Estimated PCD: 2022-02-11
Drug
Motixafortide
Clinical trial
Phase Ib Study of Fludarabine, Cytarabine (Ara-C) and Pegylated Erwinase (Pegcrisantaspase) in Patients With Relapsed or Refractory Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Pegcrisantaspase
Clinical trial
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-04-02
Clinical trial
An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2023-11-08
Drug
mFOLFOX6
Product
Posaconazole
Clinical trial
A Prospective, Single-arm Clinical Study of Bridging Allogeneic Stem Cell Transplantation After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in Relapsed/Refractory Ph-ALL and B-cell Lymphoma Patients
Status: Not yet recruiting, Estimated PCD: 2024-12-30
Product
chidamide
Clinical trial
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-06-15
Clinical trial
Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Status: Terminated, Estimated PCD: 2020-04-02
Clinical trial
Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Status: Not yet recruiting, Estimated PCD: 2027-02-24
Product
Actinium Ac 225-DOTA-Daratumumab
Product
Daratumumab
Product
Indium In 111-DOTA-Daratumumab
Clinical trial
Clinical Study on the Efficacy and Safety of Auto-HSCT in Adult Patients With Burkitt Lymphoma, Lymphoblastic Lymphoma, and Acute Lymphoblastic Leukemia Who Received TCCA Conditioning Regimen
Status: Recruiting, Estimated PCD: 2026-08-31
Product
Thiotepa, Cyclophosphamide, Cladribine, and Cytarabine
Clinical trial
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease After Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies and Myelodysplasia
Status: , Estimated PCD: 2024-08-01
Product
Interferon gamma-primed human bone marrow-derived mesenchymal stromal cells
Clinical trial
Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2024-10-08
Product
Dilanubicel
Clinical trial
Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment
Status: Completed, Estimated PCD: 2022-09-20
Product
Post-Transplant Cyclophosphamide
Clinical trial
Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of Rituximab
Status: Completed, Estimated PCD: 2018-04-18
Product
CMC-544
Clinical trial
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Drug
FOLFOXIRI
Product
Intrathecal Triples
Drug
Erwinia asparaginase
Clinical trial
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Status: Recruiting, Estimated PCD: 2025-12-25
Clinical trial
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases
Status: Completed, Estimated PCD: 2018-12-14
Clinical trial
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Recipients With Hematologic Malignancies (HM)
Status: Recruiting, Estimated PCD: 2026-09-01
Product
Orca-Q
Clinical trial
Pragmatic Clinical Trial of CD19 and CD22 CAR T-cell Sequential Therapy Versus Single CD19 CAR T-cell Bridging to Transplantation for Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2042-12-01
Product
CD19 CAR T-cell
Product
CD22 CAR T cells
Clinical trial
A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.
Status: Active (not recruiting), Estimated PCD: 2025-02-07
Clinical trial
Single Center Pilot Study to Investigate the Efficacy of Adding Itacitinib to Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning Matched Donor Hematopoietic Cell Transplantation With Peripheral Blood Stem Cells as Graft Source
Status: Recruiting, Estimated PCD: 2024-04-28
Clinical trial
Safety and Feasibility of On-Site Manufacture of CD19 CAR T Cells Using the CliniMACS Prodigy in Pediatric and Young Adult Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
CD19 specific Chimeric Antigen Receptor T Cell
Clinical trial
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma
Status: Recruiting, Estimated PCD: 2024-10-31
Product
Dexrazoxane
Clinical trial
Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Status: Active (not recruiting), Estimated PCD: 2026-12-31
Clinical trial
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction
Status: Not yet recruiting, Estimated PCD: 2025-08-31
Clinical trial
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Triple IT
Clinical trial
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2028-11-11
Product
Vincristine Sulfate
Clinical trial
Autologous and Donor-derived CD7 CAR T-cell Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma: a Single-center, Open-label, Phase Ⅰ/Ⅱ Clinical Trial
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Autologous CD7 CAR T-cell
Product
Prior-HSCT donor-derived CD7 CAR T-cell
Product
Donor-derived CD7 CAR T-cell
Clinical trial
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Diphenhydramine
Clinical trial
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Vactosertib
Clinical trial
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With High-Risk CD19+ Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-09-24
Product
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
Product
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Clinical trial
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Product
CD19/CD22 CAR T-Cells
Product
Ibuprofen
Clinical trial
A Pilot Safety Trial of STING-dependent Activators (STAVs) and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Status: Withdrawn, Estimated PCD: 2025-11-30
Product
STING-Dependent Activators
Product
Dendritic Cell Vaccine
Clinical trial
TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Zoledronate
Clinical trial
IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-12-15
Product
Autologous Hematopoietic Stem Cells
Product
Ranitidine
Clinical trial
A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Siltuximab
Clinical trial
Phase 1/2b Trial of Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells Manufactured Using the CliniMACS Prodigy Platform for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Recruiting, Estimated PCD: 2027-09-20
Product
Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells
Drug
Tocilizumab
Clinical trial
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Gene-modified T cells
Clinical trial
The Safety and Clinical Efficacy of Human CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR)-T Cell Therapy for Subjects With Measurable Residual Disease(MRD)-Positive B Cell Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2023-11-01
Product
anti-CD19/CD22 CAR-T cells
Product
DS-1594b
Clinical trial
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Status: Active (not recruiting), Estimated PCD: 2023-06-23
Product
Voriconazole
Clinical trial
A Multicenter, Single-arm, Open-end Study of Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Philadelphia Chromosome Negative Acute B Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2024-01-05
Clinical trial
Phase I/II Study Assessing Radioligand Therapy (RLT) Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.
Status: Not yet recruiting, Estimated PCD: 2027-05-15
Product
177Lu-PentixaTher
Product
Ixazomib
Clinical trial
Safety, Tolerability and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allogeneic Haematopoietic Stem Cell Transplantation and Sequential Donor-derived CD22 CAR Therapy in Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia: a Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2026-06-15
Product
Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy
Clinical trial
A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-10-11
Clinical trial
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Status: Active (not recruiting), Estimated PCD: 2024-12-15
Product
Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes
Product
Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes
Clinical trial
Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2024-12-13
Product
Basiliximab
Clinical trial
Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic Leukaemia
Status: Recruiting, Estimated PCD: 2030-03-01
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)
Status: Active (not recruiting), Estimated PCD: 2016-06-01
Drug
rapamycin
Clinical trial
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Active (not recruiting), Estimated PCD: 2014-03-21
Product
TMZ
Product
Veliparib
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
Status: Terminated, Estimated PCD: 2020-12-10
Product
Abemaciclib
Product
CART22-65s
Clinical trial
Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) Alone and When Co-administered With Humanized Anti-CD19 Chimeric Antigen Receptor Redirected T Cells (huCART19) In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2036-01-01
Product
huCART19
Clinical trial
A Phase IB/II Study of Blinatumomab in Patients With Pre B-cell Acute Lymphoblastic Leukemia (ALL) and B-cell Non-Hodgkin Lymphoma (NHL) as Post-allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2025-01-10
Product
HSCT with TBI Regimen
Product
Abiraterone
Product
Afatinib
Clinical trial
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
Status: Completed, Estimated PCD: 2022-09-19
Product
Bicalutamide
Product
Dabrafenib
Clinical trial
Phase 2 Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity (A3B1) Conjugated With the Co-stimulatory Regions 4-1BB and CD3z (ARI-0001 Cells) in Patients With CD19+ Acute Lymphoid Leukemia Resistant or Refractory to Therapy
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
ARI-0001
Product
Dacomitinib
Drug
UTD1
Clinical trial
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2027-11-30
Drug
AN0025
Clinical trial
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients
Status: Active (not recruiting), Estimated PCD: 2022-08-01
Product
PEG-Asparaginase
Drug
etoposide
Drug
Docetaxel
Clinical trial
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL)
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Ziftomenib
Clinical trial
A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years With Newly-diagnosed Philadelphia-negative ALL.
Status: Recruiting, Estimated PCD: 2023-12-30
Product
Calaspargase pegol
Clinical trial
A Phase 1 Study of Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) or Acute Myeloid Leukemia (AML)
Status: Withdrawn, Estimated PCD: 2023-02-15
Product
STI-6129
Product
Part 2
Clinical trial
Phase 2 Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Recruiting, Estimated PCD: 2028-11-15
Clinical trial
A Pilot Study of Targeted Daunorubicin Dosing to Overcome Chemotherapeutic Resistance in Children With Relapsed or Refractory Acute Leukemia
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
CASPALLO: A Phase I Study Evaluating the Use of Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2011-11-01
Product
Allodepleted T Cells
Drug
Erlotinib
Clinical trial
A Multicentre, Phase II Randomized Study, Open-label, With 2-arm Parallel Group, Comparing the Pharmacokinetics of the Liquid and the Lyophilized Formulations of Pegaspargase (S95014) in Treatment of Paediatric Patients With Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2022-05-20
Product
S95014
Product
Liquid S95014
Clinical trial
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
Status: Active (not recruiting), Estimated PCD: 2020-09-30
Clinical trial
A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia
Status: Recruiting, Estimated PCD: 2026-06-01
Product
CD19-CAR T-cells
Product
Pegylated asparaginase
Drug
doxorubicin
Clinical trial
Venetoclax in Combination With Asparaginase-Containing Pediatric-Inspired Chemotherapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell Leukemia, and Mixed Phenotype Acute Leukemia
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Copanlisib
Clinical trial
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia
Status: Withdrawn, Estimated PCD: 2023-09-01
Product
Hydrocortisone Sodium Succinate
Product
Liposome-encapsulated Daunorubicin-Cytarabine
Clinical trial
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Chimeric Antigen Receptor T-Cell Therapy
Clinical trial
A Phase1 Study at Stanford of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Palbociclib
Clinical trial
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Status: Recruiting, Estimated PCD: 2028-12-01
Product
PEG asparaginase
Clinical trial
A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
Status: Not yet recruiting, Estimated PCD: 2027-12-21
Product
Asparaginase Erwinia chrysanthemi
Clinical trial
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of CMV-MVA Triplex Vaccine in Adult Recipients of Haploidentical Hematopoietic Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2030-04-07
Product
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Clinical trial
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Myeloablative Allogeneic Stem Cell Transplant
Status: Not yet recruiting, Estimated PCD: 2025-10-29
Product
ATG Combined with Tacrolimus and Mini Methotrexate
Clinical trial
Administration of Donor-Derived Multi-Tumor-Associated Antigen (TAA)-Specific T Cells to Patients With ALL
Status: Active (not recruiting), Estimated PCD: 2019-10-29
Product
MultiTAA-specific T cells
Clinical trial
Single-Arm PharmacoKinetic/PharmacoDynamic and Safety Study of Eryaspase (GRASPA®) for Patients With Hypersensitivity to PEG-Asparaginase, Diagnosed With Ph(-) Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2020-08-01
Product
GRASPA
Drug
Atezolizumab
Product
HSCT
Clinical trial
A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Status: Recruiting, Estimated PCD: 2028-02-23
Product
19-28z/IL-18 CAR T cells
Clinical trial
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Status: Active (not recruiting), Estimated PCD: 2018-12-28
Product
Sapanisertib
Clinical trial
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Status: Recruiting, Estimated PCD: 2026-01-15
Product
Anti-CD19 CAR-T cells
Clinical trial
Venetoclax, Cladribine Plus Low-dose Cytarabine for Relapsed/Refractory Philadelphia Chromosome-negative (Ph-) B-cell Acute Lymphoblastic Leukemia (B-ALL): a Single-arm, Multicenter Study
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Cladribine
Clinical trial
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Levocarnitine
Clinical trial
Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Cytokine-treated Veto Cells
Clinical trial
Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide With Abatacept, Vedolizumab and Calcineurin Inhibitor at Children and Young Adults With Hemoblastosis After Hematopoietic Stem Cell Transplantation From an Unrelated or Haploidentic Donor
Status: Active (not recruiting), Estimated PCD: 2024-08-15
Product
GVHD prevention
Clinical trial
CD34 Selected Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning and CD8+ Memory T Cell Infusion For Patients With Myelodysplastic Syndrome, Acute Leukemia, and Chronic Myelogenous Leukemia
Status: , Estimated PCD: 2025-02-01
Product
CD8+ Memory T Cell Infusion
Clinical trial
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study
Status: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease
Status: Completed, Estimated PCD: 2020-10-09
Product
Mycophenolate mofetil
Product
Darolutamide
Clinical trial
The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008
Status: Completed, Estimated PCD: 2016-02-28
Clinical trial
A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants With Acute Leukemia
Status: Recruiting, Estimated PCD: 2026-02-16
Product
JNJ-75276617
Clinical trial
Reduced Intensity Conditioning Regimen for Elderly or High Comorbidity Burden Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Enasidenib
Clinical trial
A Phase I/Ib Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or Bendamustine
Status: Active (not recruiting), Estimated PCD: 2025-08-25
Product
Bendamustine
Product
Gilteritinib
Drug
Entrectinib
Clinical trial
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Active (not recruiting), Estimated PCD: 2029-05-01
Product
iCaspase9-transduced T cells
Product
AP1903
Clinical trial
Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2022-12-31
Product
Curcumin
Clinical trial
A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Indium In 111-DOTA-Basiliximab
Product
Palifermin
Product
Yttrium Y 90 Basiliximab
Clinical trial
Ponatinib for the Management of Minimal Residual Disease (MRD) and Hematologic Relapse in Adult Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) Patients
Status: Recruiting, Estimated PCD: 2024-11-01
Product
EZN-3042
Clinical trial
Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Status: Recruiting, Estimated PCD: 2036-05-01
Drug
huCART19-IL18
Drug
tacrolimus
Clinical trial
Aflac LL1602 ENCERT: A Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Relapsed T Cell Lymphoblastic Leukemia/Lymphoma
Status: Completed, Estimated PCD: 2023-06-29
Product
Everolimus
Clinical trial
Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2026-04-22
Product
iC9-CAR19
Product
Letermovir
Clinical trial
ALL Adult Consortium Trial: Adult ALL Trial
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Methylprednisone
Product
6-MP
Product
E. coli Asparaginase
Clinical trial
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia in Adults
Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Status: Recruiting, Estimated PCD: 2041-10-01
Product
Cryopreserved Cord Blood Units
Product
Cabazitaxel
Product
Cabozantinib
Product
Vincristin
Product
Peg-asparaginase
Product
Intrathecal Suspension
Product
Levetiracetam
Drug
Celecoxib
Product
Cobimetinib
Product
Anti-CD123 ADC IMGN632
Clinical trial
Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
Tagraxofusp-erzs
Clinical trial
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
Status: Terminated, Estimated PCD: 2022-11-11
Clinical trial
Single Cycle of Blinatumomab Followed by High-dose Chemotherapy in the Induction Therapy for Ph-negative Acute Lymphoblastic Leukemia in Adults
Status: Completed, Estimated PCD: 2024-02-29
Clinical trial
BMT-06: Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Cyclophosphamide and Post-Transplant Cyclophosphamide Conditioning for Partially HLA Mismatched (Haploidentical) Allogeneic Transplantation in Patients With Acute Leukemia and Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Arm1
Product
Enzalutamide
Clinical trial
Phase II Study Assessing the Efficacy and Safety of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of High Risk Acute Lymphoblastic Leukemia
Status: Not yet recruiting, Estimated PCD: 2025-05-20
Clinical trial
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Status: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
Implementation of Innovative Techniques in Routine Diagnosis of Childhood Acute Leukemia: Analysis of Genome and Transcriptome by Micro-array
Status: Completed, Estimated PCD: 2016-05-26
Product
Blood draw
Clinical trial
Cytokine-induced Killer(CIK) Cell Therapy and Its Impact on Early Functional Exhaustion of Chimeric Antigen Receptor-T(CAR-T) Cells in Relapsed or Refractory Acute B-Lymphoblastic Leukemia: A Prospective Study
Status: Not yet recruiting, Estimated PCD: 2025-05-30
Product
Peripheral Blood Lymphocytes
Product
CIK cell
Clinical trial
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Status: Recruiting, Estimated PCD: 2025-03-31
Product
VIC- 1911
Clinical trial
An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)
Status: Completed, Estimated PCD: 2016-03-30
Clinical trial
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Status: Terminated, Estimated PCD: 2023-05-03
Product
Selumetinib
Clinical trial
Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)
Status: Recruiting, Estimated PCD: 2025-04-30
Product
Anti-CD19/CD20/CD22 CAR T-Cells
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Status: Completed, Estimated PCD: 2018-04-12
Clinical trial
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA
Status: Recruiting, Estimated PCD: 2028-07-11
Product
ALLR3
Clinical trial
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
Status: Completed, Estimated PCD: 2017-11-14
Drug
alemtuzumab
Drug
lenalidomide
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol C Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Status: Not yet recruiting, Estimated PCD: 2030-10-01
Product
Intrathecal chemotherapy
Clinical trial
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
Status: Active (not recruiting), Estimated PCD: 2023-02-22
Clinical trial
Measurable Residual Disease Driven Strategy for One or Two Infusions of Non- Viral, Transposon-manipulated CARCIK (CD19) Cells: A Phase II Study in Pediatric and Adult Patients With Relapsed/Refractory B Cell Precursor ALL (BCP-ALL)
Status: Recruiting, Estimated PCD: 2024-12-01
Product
PTG-CARCIK-CD19
Clinical trial
CD5 Chimeric Antigen Receptors (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: a Single-center, Open-label, Non-randomized, Phase 1/2 Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Product
Autologous CD5 CAR T-cells
Product
Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells
Product
Donor-derived CD5 CAR T-cells
Clinical trial
A Phase I, First in Human, Open-label Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
Status: Recruiting, Estimated PCD: 2023-12-27
Product
INA03
Clinical trial
Clinical Study of rATG Individualized Administration for Prevention of GVHD and Maintenance of GVL in Haploidentical Hematopoietic Stem Cell Transplantation.
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Individual ATG
Clinical trial
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Mycophenolate Sodium
Product
Treosulfan
Clinical trial
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803
Status: Completed, Estimated PCD: 2021-06-01
Product
ALT803
Clinical trial
A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations
Status: Not yet recruiting, Estimated PCD: 2026-09-11
Clinical trial
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Status: Recruiting, Estimated PCD: 2024-01-01
Product
Darzalex Faspro
Clinical trial
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-02-11
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Completed, Estimated PCD: 2016-08-01
Drug
Plerixafor
Clinical trial
A Multi-centre Phase II Trial of GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation Comparing Thymoglobulin vs. Calcineurin Inhibitor or Sirolimus-based Post-transplant Cyclophosphamide
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Thymoglobulin
Drug
sirolimus
Clinical trial
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
Status: Active (not recruiting), Estimated PCD: 2024-11-22
Clinical trial
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector - a Unicenter Phase I/II Clinical Trial
Status: Recruiting, Estimated PCD: 2024-01-01
Product
CD19.CAR T Cells
Clinical trial
SJCAR19: A Phase I/II Study Evaluating SJCAR19 (CD19-Specific CAR Engineered Autologous T-Cells) in Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2023-07-01
Product
CD19-specific CAR engineered autologous T-cells
Product
Revumenib
Clinical trial
A Phase Ⅱ, Open Label, Single Arm, Single-Center Study to Evaluate the Efficacy and Safety of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
Status: Completed, Estimated PCD: 2024-04-13
Product
Flumatinib
Clinical trial
Efficacy Evaluation of Post-transplant Cyclophosphamide-based Graft-versus-host Disease Prophylaxis With ATG, Calcineurin Inhibitor-free, for Matched-sibling or Matched-unrelated Transplantation
Status: Not yet recruiting, Estimated PCD: 2031-06-01
Clinical trial
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed/ Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2025-06-01
Product
CAR-20/19-T cells
Clinical trial
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
Status: Not yet recruiting, Estimated PCD: 2023-04-01
Clinical trial
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) +/- Rituximab (R) + Tafasitamab-cxix for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative (Ph-) B-cell Lymphoblastic Lymphoma/Leukemia (B-ALL)
Status: Recruiting, Estimated PCD: 2025-09-01
Drug
Tafasitamab
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-protocol B Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Status: Not yet recruiting, Estimated PCD: 2030-10-01
Clinical trial
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease
Status: Active (not recruiting), Estimated PCD: 2026-07-01
Clinical trial
A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
Status: Completed, Estimated PCD: 2021-04-30
Clinical trial
Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
Umbilical Cord Blood Transplantation From Unrelated Donors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
CD19-Chimeric Antigen Receptor-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2023-06-30
Product
CD19-CAR-T2
Clinical trial
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Status: Recruiting, Estimated PCD: 2024-07-01
Product
HPC,A
Clinical trial
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301; Progress II)
Status: Completed, Estimated PCD: 2020-10-05
Clinical trial
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Status: Not yet recruiting, Estimated PCD: 2029-10-01
Product
Decitabine
Clinical trial
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Status: Active (not recruiting), Estimated PCD: 2019-06-30
Clinical trial
Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation
Status: Completed, Estimated PCD: 2023-02-13
Clinical trial
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Status: , Estimated PCD: 2025-03-01
Drug
Allopurinol
Clinical trial
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2018-03-04
Product
CMVpp65-A*0201
Clinical trial
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Phase I Clinical Trial of Human AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia)
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Fully human anti CD19 CAR-T Cell
Clinical trial
Mitochondrial Cofactors for the Treatment of Hyperbilirubinemia Due to PEG-Asparaginase and or Inotuzumab Ozogamicin in Patients With Acute Lymphoblastic Leukemia (ALL)
Status: Recruiting, Estimated PCD: 2035-12-31
Product
Vitamin B Complex
Clinical trial
Pilot Study on the Reduced Intravenous Fluids to Improve Clearance of High-Dose Methotrexate (HDMTX) in Children With Lymphoma or Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2022-12-07
Product
Intravenous fluids
Clinical trial
Phase I Study of the Administration of Multi-Virus-Specific Cytotoxic T Lymphocytes Expressing CD19 Chimeric Receptors for Prophylaxis or Therapy of Relapse of CD19 Positive Malignancies Post Hematopoietic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2016-04-01
Product
CD19CAR/virus specific T cells
Product
Benadryl
Clinical trial
Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
Status: Terminated, Estimated PCD: 2022-06-30
Product
Irradiated Allogeneic Cells
Clinical trial
A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2024-05-22
Product
ATG 5.0
Clinical trial
Chinese Children Cancer Group Relapsed Acute Lymphoblastic Leukemia 2017 Study
Status: Completed, Estimated PCD: 2023-02-15
Clinical trial
Phase II Study of Sequential Chimeric Antigen Receptor T Cell Targeting at Different B-cell Antigens Treating Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Children
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Chimeric Antigen Receptor T Cell
Product
Rituximab
Clinical trial
A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2017-01-01
Clinical trial
Venetoclax (VEN)+Azacytidine (AZA) Followed by Modified BUCY Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Status: Recruiting, Estimated PCD: 2025-01-20
Product
VEN+AZA
Clinical trial
A Pilot Study of CD19-Specific Car T Cells as Consolidation for Older Adults With Acute Lymphoblastic Leukemia in First Remission
Status: Recruiting, Estimated PCD: 2026-07-24
Product
Autologous Anti-CD19 CAR-expressing T Lymphocytes
Clinical trial
A Phase 2 Clinical Study of SHP674 in Patients With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
Status: Completed, Estimated PCD: 2021-02-12
Product
SHP674
Product
Anti-thymocyte globulin
Clinical trial
Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors
Status: Completed, Estimated PCD: 2011-08-01
Product
Alentuzumab
Product
Globulina antilinfocitaria
Clinical trial
A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
Status: Recruiting, Estimated PCD: 2024-10-13
Product
Anti-Thymocyte globulin
Clinical trial
Phase 1, Open Label Study of CRISPR-CAR Genome Edited T Cells (PBLTT52CAR19) in Relapsed /Refractory B Cell Acute Lymphoblastic Leukaemia
Status: Completed, Estimated PCD: 2024-03-05
Product
PBLTT52CAR19
Clinical trial
Multicentered Phase II Study Evaluating the Activity and Toxicity of Liposomal Cytarabine in the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia With Resistent or Relapsed Central Nervous System Involvement
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Liposomal Cytarabine
Product
Umbilical cord blood cell infusion
Clinical trial
Study for Safety and Efficacy Evaluation of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (R/R Ph + ALL）
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Olverembatinib
Clinical trial
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Anti-CD19 CAR T-cells
Clinical trial
Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Childhood and Adolescent Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2023-12-01
Product
Natural Killer Cells
Clinical trial
A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic Myelogenous Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Status: Completed, Estimated PCD: 2019-12-15
Product
Temsirolimus
Clinical trial
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
Status: Active (not recruiting), Estimated PCD: 2017-09-30
Clinical trial
A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2024-10-30
Drug
Olverembatinib
Product
EAGD T-cell infusion
Clinical trial
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Product
NKTR-255
Clinical trial
Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells Following Commercial CD19 CAR T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-06-01
Product
CD22CART
Drug
Tisagenlecleucel
Clinical trial
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
Status: Recruiting, Estimated PCD: 2026-04-15
Product
TRX103
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Status: Recruiting, Estimated PCD: 2029-04-01
Product
Trametinib
Clinical trial
Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide With Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis After Hematopoietic Stem Cell Transplantation From an Unrelated or Haploidentic Donor
Status: Recruiting, Estimated PCD: 2026-12-01
Drug
JAKi
Clinical trial
Anti-Covid-19 Vaccine Protection in Immunocompromised Children (1 to 15 Years Old) With Acute Leukemia and Their Siblings (≥12 Years Old). Phase I-II Trial Evaluating Post-vaccine Safety and Humoral and Cellular Immunogenicity.
Status: Completed, Estimated PCD: 2022-02-28
Product
COMIRNATY (BNT162b2)
Clinical trial
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Drug
CAR-T cells
Clinical trial
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Phase I
Product
Phase II
Clinical trial
A Phase I, Dose-finding Study of the Oral, Dual Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Status: Completed, Estimated PCD: 2017-12-01
Product
BEZ235
Clinical trial
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Status: Recruiting, Estimated PCD: 2028-05-22
Product
Conditioning Chemotherapy
Product
Cord blood graft
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2024-02-02
Clinical trial
Phase Ib Study to Evaluate Humanized CD19-Specific CAR T Cells Following Lymphodepleting Chemotherapy in Adult Patients With Relapsed/Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2025-08-06
Clinical trial
Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Stem Cell Mobilization Therapy
Clinical trial
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2023-08-21
Product
Melphalan
Clinical trial
A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Drug
prednisone
Drug
vinca alkaloids
Product
asparaginase
Drug
dexamethasone
Drug
cytarabine
Product
hydrocortisone
Product
E. coli L-asparaginase
Clinical trial
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia
Status: Not yet recruiting, Estimated PCD: 2030-12-01
Clinical trial
Randomized Trial of Benadamustine Versus Ruxolitinib With Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
Safety and Feasibility of On-Site Manufacture of CD19 CAR T Cells Using the CliniMACS Prodigy in Pediatric and Young Adult Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
Pegylated L-Asparaginase
Clinical trial
Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2028-12-31
Product
Lymphodepletion with Fludarabine
Product
Lymphodepletion with cyclophosphamide
Product
CD19/22 CAR T-cells
Clinical trial
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia
Status: Active (not recruiting), Estimated PCD: 2021-09-13
Product
T-cell Antigen Presenting Cells expressing truncated CD19
Clinical trial
AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination With Chemotherapy in Patients With Relapsed/Refractory Leukemias Harboring Alterations in KMT2A/MLL, Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Chemotherapy Regimen 1
Product
Chemotherapy Regimen 2
Clinical trial
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2025-05-31
Product
Hematopoietic Cell Transplantation Conditioning Regimen
Clinical trial
Phase 1-2a Trial to Determine the Feasibility and Safety of a Single Dose of Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Adult and Pediatric Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, After Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2021-03-31
Product
CARCIK-CD19
Clinical trial
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)
Status: Terminated, Estimated PCD: 2008-04-01
Product
KW-2449
Product
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Product
Peripheral Blood Stem Cell
Clinical trial
Prospective Single Group Study Combined Immuno-hemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
Status: Recruiting, Estimated PCD: 2029-07-01
Product
Risk-adapted therapy with chemotherapy, immunotherapy, and stem cell transplantation
Clinical trial
Efficacy and Safety of Molecular Targeted Therapy Combined With Chemotherapy and Sequential CAR-T Cells in Newly Diagnosed Adult Patients With Philadelphia Chromosome-Positive B-cell Acute Lymphoblastic Leukemia
Status: Not yet recruiting, Estimated PCD: 2026-06-01